---
title: "688566.SH (688566.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688566.SH/news.md"
symbol: "688566.SH"
name: "688566.SH"
parent: "https://longbridge.com/en/quote/688566.SH.md"
datetime: "2026-05-21T02:12:44.270Z"
locales:
  - [en](https://longbridge.com/en/quote/688566.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688566.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688566.SH/news.md)
---

# 688566.SH (688566.SH) — Related News

### [Jibeier Pharmaceutical: 2025 net profit growth of 19%, with the ramp-up of Niqunluo tablets resonating with the advancement of the innovation pipeline](https://longbridge.com/en/news/284213600.md)
*2026-04-27T12:16:34.000Z*
> On the evening of April 27th, Jibeier Pharmaceutical (688566) simultaneously disclosed its 2025 annual report and the fi

### [Jibeier Pharmaceutical: Net profit in the first quarter was 41.9942 million yuan, a year-on-year decrease of 15.21%](https://longbridge.com/en/news/284194966.md)
*2026-04-27T10:22:42.000Z*
> Jibeier announced that its operating revenue in the first quarter of 2026 was 226 million yuan, a year-on-year increase 

### [Jibeier Pharmaceutical: Net profit of 262 million yuan in 2025, a year-on-year increase of 19.28%](https://longbridge.com/en/news/284194902.md)
*2026-04-27T10:22:24.000Z*
> Jibeier Pharmaceutical announced that the operating revenue for 2025 is expected to be 966 million yuan, a year-on-year 

### [Jibeier Pharmaceutical grants 1.6 million restricted shares to 93 incentive recipients](https://longbridge.com/en/news/282343008.md)
*2026-04-10T12:19:02.000Z*
> On April 10, 2026, Jibeier Pharmaceutical held a board meeting and approved the grant of 1.6 million restricted shares t

### [A-share subscription | Zuxing New Materials (920078.BJ) opens for subscription, dedicated to the application research of aluminum pigments and fine spherical aluminum powder](https://longbridge.com/en/news/278284169.md)
*2026-03-08T22:33:03.000Z*
> Zuxing New Materials (920078.BJ) opened for subscription on March 9, with an issue price of 6.98 yuan per share, a subsc

### [Jibeier Pharmaceutical: 2025 performance preliminary report net profit growth of 18%, new drug research and development is actively progressing](https://longbridge.com/en/news/277204183.md)
*2026-02-27T13:19:47.000Z*
> On the evening of February 27th, Jibeier disclosed its performance preliminary report for the fiscal year 2025. Accordin

### [Jibeier Pharmaceutical: Net profit in 2025 is expected to increase by 17.94% year-on-year](https://longbridge.com/en/news/277167007.md)
*2026-02-27T08:48:55.000Z*
> Jibeier Pharmaceutical announced that the total operating revenue for 2025 reached RMB 964,930,489.25, an increase of 7.

### [Global beverage giant Diageo lowers profit expectations and cuts dividends, with stock price plummeting 8%](https://longbridge.com/en/news/276896697.md)
*2026-02-25T13:40:10.000Z*
> Global beverage giant Diageo has lowered its sales and profit expectations for 2026 and cut its dividend to 20 cents per

### [Jibeier Pharmaceutical: Obtained the invention patent for "A Taxane Derivative and Its Preparation Method and Application"](https://longbridge.com/en/news/270127892.md)
*2025-12-18T08:33:39.000Z*
> Jibeier Pharmaceutical announced that it has obtained an invention patent for "A Paclitaxel Derivative and Its Preparati

### [Founder Securities: The trend of innovative drugs going overseas has become a trend, and new technology development leads the future](https://longbridge.com/en/news/267444599.md)
*2025-11-26T02:29:05.000Z*
> The research report from Founder Securities points out that the trend of innovative drugs going overseas has emerged, wi